Pricing Log in Create free account

ALX Oncology Holdings Inc. (ALXO) vs Canton Strategic Holdings, Inc. (CNTN)

ALX Oncology Holdings Inc. and Canton Strategic Holdings, Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. and Canton Strategic Holdings, Inc. are of similar size ($149.0M and $138.3M). ALX Oncology Holdings Inc. has negative trailing earnings, so its P/E is not meaningful; Canton Strategic Holdings, Inc. trades at 9.0×. Across the 10 metrics below, Canton Strategic Holdings, Inc. leads on 9 and ALX Oncology Holdings Inc. on 1.

Valuation

Metric ALXO CNTN Biotechnology median
P/E n/m 9.01 8.50
P/S 58.97 n/m 9.71
P/B 1.06 0.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.40 n/m 9.21
Earnings yield (106.60%) 11.10% (33.15%)
Free cash flow yield (49.32%) (6.01%) (25.50%)

Profitability

Metric ALXO CNTN Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.65%) (43.10%) (56.36%)
Return on assets (63.16%) (34.60%) (48.04%)
Return on invested capital (673.30%) (8.11%) 0.00%

Growth

Metric ALXO CNTN Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 26.36% 88.10% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALXO CNTN Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 9.71 15.70 4.72
Net debt to EBITDA 0.34 0.85 0.96

Dividend

Metric ALXO CNTN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALXO CNTN Biotechnology median
Market cap 138.28m 149.01m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack